Screener
CytomX Therapeutics CTMX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 17,598 | 13,322 | 36,836 | 32,189 |
| General and administrative | 7,601 | 6,622 | 18,294 | 16,050 |
| Total operating expenses | 25,199 | 19,944 | 55,130 | 48,239 |
| Income (loss) from operations | (23,781) | (1,286) | (43,453) | 21,336 |
| Interest income | 3,157 | 1,178 | 4,647 | 2,133 |
| Other income | 18 | 17 | 11 | 28 |
| Income (loss) before income taxes | (20,606) | (91) | (38,795) | 23,497 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's other operating expenses?
- CytomX Therapeutics (CTMX) reported other operating expenses of $25.2M in Q2 2026.
- How has CytomX Therapeutics's other operating expenses changed year-over-year?
- CytomX Therapeutics's other operating expenses increased by 26.3% year-over-year, from $19.94M to $25.2M.
- What is the long-term trend for CytomX Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), CytomX Therapeutics's other operating expenses has grown at a -10.5% compound annual growth rate (CAGR), from $153.35M to $98.57M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about CytomX Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude